Skip to content
buyWeak

Patrick G Lepore bought $44k of YARW

director at VYNE Therapeutics Inc.. 15,000 shares at an average of $2.92, traded Jan 15, 2025, filed Jan 16, 2025.

Conviction score
27
Value
$44k
15,000 shares
Holdings after
51,472
+41% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $44k at market
    +6
  • Relative to holdings
    Holdings up 41%
    +6
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

YARWOct 9, 2026 · close 19.71
Since filing Jan 16, 2025: -72.9%SPY +34.2% · excess -107.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001415889-25-001574, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 15, 2025POpen-market purchase
Common Stock
+15,000$2.92$44k51,472Jan 16, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Patrick G Lepore bought $44k of YARW | InsiderTell